# Omada Health, Inc. (OMDA)

> Source: Nexqual · https://nexqual.com/OMDA · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Omada Health, Inc. (OMDA), nexqual.com/OMDA" · informational, not investment advice.

**Price:** USD 18.98 (-3.46% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 19.66 · day 18.58–19.71 · 52w 10.28–26.92 · market cap $1.16B · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $310M, net income $4.3M (1.4% margin), free cash flow $22.7M (SEC filings).
- Valuation: P/E 269.9x.
- Analysts: Buy (mean 1.75 on a 1–5 scale) (12 analysts), mean target USD 28.42 (range 22–35).
- Total return with dividends: 1Y -26.1% vs S&P 500 +14.9%; 5Y -17.5% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 0.1, revenue estimate $85.6M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|
| Revenue | $123M | $170M | $260M | $310M |
| Gross profit | $70.0M | $103M | $171M | — |
| Operating income | -$66.0M | -$43.7M | -$12.0M | -$464K |
| Net income | -$67.5M | -$47.1M | -$12.8M | $4.3M |
| EPS (diluted) | -$9.52 | -$6.11 | -$0.35 | — |
| Free cash flow | -$50.2M | -$34.8M | $16.9M | $22.7M |
| Gross margin | 57.0% | 60.6% | 65.7% | — |
| Operating margin | -53.8% | -25.7% | -4.6% | -0.1% |
| Net margin | -55.0% | -27.8% | -4.9% | 1.4% |
| Revenue growth | — | +38.3% | +53.2% | — |
| Cash + short-term investments | $116M | $76.4M | $222M | — |
| Total debt | — | $29.8M | $0K | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 269.9x · P/S 3.8x · P/FCF 51.1x · P/B 4.6x · FCF yield 1.96% · Earnings yield 0.37%

## Analysts
Consensus Buy (mean 1.75 on a 1–5 scale), 12 analysts; mean target USD 28.42 (low 22, high 35).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | Freedom Capital Markets | Maintained | Buy | $35 |
| 2026-09-14 | Freedom Capital Markets | Maintained | Buy | $35 |
| 2026-09-11 | Barclays | Target raised | Overweight | $25 → $27 |
| 2026-09-11 | Needham | Reiterated | Buy | $28 |
| 2026-09-11 | BTIG | Reiterated | Buy | $35 |
| 2026-08-14 | JP Morgan | Target raised | Overweight | $26 → $30 |
| 2026-08-14 | Citizens | Target raised | Market Outperform | $27 → $32 |
| 2026-08-12 | Baird | Target raised | Neutral | $15 → $25 |
| 2026-08-10 | BTIG | Target raised | Buy | $30 → $35 |
| 2026-08-03 | Barclays | Target raised | Overweight | $20 → $25 |
| 2026-07-21 | Canaccord Genuity | Target raised | Buy | $24 → $28 |
| 2026-07-20 | Citizens | Target raised | Market Outperform | $21 → $27 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2025-06-02) |
|---|---|---|
| Total return | -26.1% | -17.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -26.2% | -12.9% |
| Volatility (annualized) | 63.3% | 69.0% |
| Max drawdown | -59.1% (Oct 2025→Feb 2026) | -56.3% (Oct 2025→Feb 2026) |

## Peers (Health Information Services)
TDOC (Teladoc Health, Inc.) USD 6.32 +0.32% · GDRX (GoodRx Holdings, Inc.) USD 3.62 +1.40% · HSTM (HealthStream, Inc.) USD 34.59 +3.22% · CERT (Certara, Inc.) USD 10.09 -0.88% · OMCL (Omnicell, Inc.) USD 37.1 +2.09% · SDGR (Schrodinger, Inc.) USD 22.6 -5.44%

## More
Full page: https://nexqual.com/OMDA · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Services | $80.7M | 91.9% | +41.7% |
| Hardware | $7.1M | 8.1% | +61.9% |
| Total revenue | $87.8M | 100% | — |

## Customer concentration

Period ended 2026-06-30: 33%, 31% of revenue from unnamed direct customers (10-Q, filed 2026-08-07).

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.10 | $0.09 | +9.9% | $85.6M | 5 |
| Next quarter (ends 2026-12-31) | $0.11 | $0.13 | -13.1% | $87.0M | 5 |
| Current fiscal year (ends 2026-12-31) | $0.44 | $0.33 | +33.5% | $338.7M | 5 |
| Next fiscal year (ends 2027-12-31) | $0.56 | $0.48 | +16.7% | $407.8M | 5 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-05): ±16.6%; last 6 reports averaged ±9%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 70.9% | ±16.6% |
| 2026-12-18 | 56 | 76.7% | ±24.7% |
| 2027-01-15 | 84 | 64.8% | ±25.4% |
| 2027-03-19 | 147 | 67.6% | ±34.8% |
| 2027-04-16 | 175 | 65.3% | ±36.7% |